Related Experiment Video
Updated: Jul 19, 2026
12:50
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
Signalling platforms that modulate the inflammatory response: new targets for drug development
Christopher A McCulloch1, Gregory P Downey, Hani El-Gabalawy
1CIHR Group in Matrix Dynamics, University of Toronto, Toronto, Canada M5S 3E2. christopher.mcculloch@utoronto.ca
Nature Reviews. Drug Discovery
|October 4, 2006
Summary
New anti-inflammatory drugs targeting interleukin-1 (IL-1) receptor clustering offer hope for patients refractory to current treatments. Understanding receptor aggregation is key to developing novel therapies for inflammatory diseases.
Area of Science:
- Immunology
- Pharmacology
- Cell Biology
Background:
- Therapeutic control of inflammation is crucial for managing prevalent human diseases.
- Anti-cytokine therapies targeting tumour-necrosis factor-alpha and interleukin-1 (IL-1) benefit some inflammatory conditions, but many patients show resistance.
- Existing treatments highlight the need for novel anti-inflammatory drug strategies.
Purpose of the Study:
- To explore the need for new anti-inflammatory drug development.
- To identify novel drug targets based on the mechanism of interleukin-1 (IL-1) receptor aggregation.
- To investigate the role of receptor clustering in IL-1 signaling pathways.
Main Methods:
- The study reviews existing literature on anti-inflammatory drug targets and mechanisms.
- It focuses on the aggregation of IL-1 receptors into multi-protein complexes at cell adhesion sites.
- The research explores the molecular components essential for IL-1 receptor clustering and signal transduction.
Main Results:
- IL-1 receptor aggregation into multi-protein complexes is a critical step in IL-1 signaling.
- Interference with this receptor clustering effectively blocks IL-1 signal transduction.
- This mechanism presents a novel avenue for therapeutic intervention.
Conclusions:
- Novel anti-inflammatory drug targets can be developed by focusing on IL-1 receptor clustering.
- Interfering with the molecules essential for receptor aggregation offers a new strategy for drug development.
- This approach holds promise for treating inflammatory diseases in patients unresponsive to current therapies.
Related Concept Videos
01:28Inflammatory Response
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:26Signal Transduction: Overview
Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Typically, signal transduction involves three...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...